Pfizer’s Pick to Head New Drug Division Leaves
This article is for subscribers only.
Pfizer Inc.’s Amy Schulman, named to head one of the company’s three new drug units starting next month, will instead leave the company.
Schulman, a deputy to Chief Executive Officer Ian Read and Pfizer’s general counsel, was chosen in July to lead one of the businesses as the New York-based company reorganizes ahead of a potential breakup. Albert Bourla, a 20-year Pfizer veteran, will now head the unit, which handles vaccines, oncology and consumer health products, Pfizer said in a statement today.